DBVT
Closed
Dbv Technologies
10.49
+1.33 (+14.52%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.1599
Day's Range: 9.13 - 10.8
Send
sign up or login to leave a comment!
When Written:
1.69
DBV Technologies is a French biopharmaceutical company that specializes in the development of innovative therapies for food allergies. The company was founded in 2002 and is headquartered in Montrouge, France. DBV Technologies is best known for its Viaskin technology, which is a non-invasive, patch-based delivery system for allergen immunotherapy.
The company's lead product candidate is Viaskin Peanut, which is currently in Phase III clinical trials for the treatment of peanut allergies. DBV Technologies is also developing Viaskin Milk, Viaskin Egg, and Viaskin Fish for the treatment of other food allergies.
DBV Technologies has partnerships with several pharmaceutical companies, including Nestle Health Science, Sanofi, and CSL Behring. The company has also received funding from various sources, including venture capital firms, government grants, and public offerings.
DBV Technologies is committed to improving the lives of patients with food allergies by developing safe and effective therapies. The company's mission is to become a global leader in the treatment of food allergies and to provide patients with a better quality of life.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate is Viaskin Peanut, which is currently in Phase III clinical trials for the treatment of peanut allergies. DBV Technologies is also developing Viaskin Milk, Viaskin Egg, and Viaskin Fish for the treatment of other food allergies.
DBV Technologies has partnerships with several pharmaceutical companies, including Nestle Health Science, Sanofi, and CSL Behring. The company has also received funding from various sources, including venture capital firms, government grants, and public offerings.
DBV Technologies is committed to improving the lives of patients with food allergies by developing safe and effective therapies. The company's mission is to become a global leader in the treatment of food allergies and to provide patients with a better quality of life.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!